<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ENLON- edrophonium chlorideÂ injection, solutionÂ </strong><br>Mylan Institutional LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_fbafffcd-4190-4043-bd2e-4f15e8664b5e"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ENLON is a short and rapid-acting cholinergic drug. Chemically, edrophonium chloride is ethyl(m-hydroxyphenyl) dimethylammonium chloride and its structural formula is:</p>
<div class="Figure">
<a name="id235"></a><img alt="Enlon Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=98a5a2f6-3194-4202-963f-0fcd28ecadbc&amp;name=91687c49-8f28-499e-9999-9b51154ad379-01.jpg">
</div>
<p>Each mL contains, in a sterile solution, 10 mg edrophonium chloride compounded with 0.45% phenol as a preservative, and 0.2% sodium sulfite as an antioxidant, buffered with sodium citrate and citric acid, and pH adjusted to approximately 5.4.</p>
<p>ENLON is intended for IV and IM use.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_019bf6a9-7995-455c-aebe-f0c9b82ba292"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">ENLON is an anticholinesterase drug. Its pharmacologic action is due primarily to the inhibition or inactivation of acetylcholinesterase at sites of cholinergic transmission. Its effect is manifest within 30 to 60 seconds after injection and lasts an average of 10 minutes.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dafb5523-ba42-4165-afb7-0842694d2fe4"></a><a name="section-2.1"></a><p></p>
<h2>Pediatric Pharmacology</h2>
<p class="First">The pharmacology of edrophonium chloride was studied in 14 infants (between 3 weeks and 11 months old) and 12 children (between 1 year and 6 years old) during a steady-state infusion of <span class="Italics">d</span>-tubocurarine during N<span class="Sub">2</span>O-halothane anesthesia and controlled ventilation for elective surgery.<span class="Sup">1</span> The ED<span class="Sub">50</span> dose (dose producing 50% antagonism of 90% neuromuscular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) for edrophonium chloride was 145 mcg/kg in infants and 233 mcg/kg in children not significantly different from that observed in adult patients; however, there was greater variability among infants and children than adults. Time to peak antagonism and duration of antagonism were similar between the two pediatric age groups and adult patients. Edrophonium chloride pharmacokinetics were studied in four infants (3 months through 7 months of age) and four children (1 through 4 years of age). Total clearance was 17.8 mL/kgâ€¢min in infants and 14.2 mL/kgâ€¢min in children. Total clearance was significantly greater in infants than in adults (8.3 + 2.9 mL/kgâ€¢min) p&lt;0.05. Elimination half-life was 73 Â± 30 minutes in infants and 99 Â± 31 minutes in children compared with 126 Â± 59 minutes in adult patients. Volume of distribution in infants and children was 1.18 Â± 0.20 L/kg and 1.22 Â± 0.74 L/kg, respectively, compared with 0.90 Â± 0.13 L/kg in adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_9e5969e0-3c64-4751-a7e1-0e5ffd779c8c"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ENLON is recommended for the differential diagnosis of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>ENLON is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> caused by curare overdosage.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_dd300dc7-97ef-4c9b-87f4-05b3f4916f41"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to anticholinesterase agents; intestinal and urinary obstructions of mechanical type.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_979a0e6b-6c73-4eba-a83e-0375517e80be"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Whenever anticholinesterase drugs are used for testing, a syringe containing 1 mg of atropine sulfate should be immediately available to be given in aliquots intravenously to counteract severe cholinergic reactions which may occur in the hypersensitive individual, whether he is normal or myasthenic. ENLON should be used with caution in patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>. The transient <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> which sometimes occurs can be relieved by atropine sulfate. Isolated instances of cardiac and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> following administration of ENLON have been reported. It is postulated that these are vagotonic effects.</p>
<p>ENLON contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a4fdb20-959a-4410-a904-07918858c302"></a><a name="section-5.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">The safety of ENLON during pregnancy or lactation in humans has not been established. Therefore, use of ENLON in women who may become pregnant requires weighing the drugâ€™s potential benefits against its possible hazards to mother and child.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d6cf9f1b-13e4-4dce-907d-be54af836a96"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Patients may develop â€œanticholinesterase insensitivityâ€? for brief or <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>. During these periods the patients should be carefully monitored and may need respiratory assistance. Dosages of anticholinesterase drugs should be reduced or withheld until patients again become sensitive to them.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d20df58-b3f8-4501-8e52-73c05447275d"></a><a name="section-6.1"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of edrophonium chloride in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> have been established in pediatric patients. (See <span class="Bold"><a href="#i4i_section_id_a3fe604b-ecf6-4d61-b1e8-091d4c1bafec">DOSAGE AND ADMINISTRATION: ENLON Test in the Differential Diagnosis of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span>: Dosage in Pediatric Patients</a></span>). The safety and effectiveness of edrophonium chloride in reversing <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> in pediatric patients have not been fully determined, although doses ranging from 0.1 mg/kg to 1.43 mg/kg have been described.<span class="Sup">2-6</span> Antagonism of nondepolarizing neuromuscular blocking drugs in pediatric patients is more rapid than in adults. Limited pharmacodynamic and pharmacokinetic data in pediatric patients have been published. (See <span class="Bold"><a href="#i4i_section_id_dafb5523-ba42-4165-afb7-0842694d2fe4">CLINICAL PHARMACOLOGY: Pediatric Pharmacology</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_5d18a2d4-6a62-41ea-a4a6-b04a6981d422"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Careful observation should be made for severe cholinergic reactions in the hyperreactive individual. The myasthenic patient in crisis who is being tested with ENLON should be observed for <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or cardiac standstill and cholinergic reactions if an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is given.</p>
<p>The following reactions common to anticholinesterase agents may occur, although not all of these reactions have been reported with the administration of ENLON, probably because of its short duration of action and limited indications:</p>
<table>
<col width="18%">
<col width="82%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">Eye:</p></td>
<td class="Toprule" valign="top"><p class="First">Increased <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, pupillary constriction, <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">spasm of accommodation</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>.</p></td>
</tr>
<tr>
<td valign="top"><p class="First">CNS:</p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>.</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Respiratory:</p></td>
<td valign="top"><p class="First">Increased tracheobronchial secretions, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, bronchiolar constriction, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of muscles of respiration, central <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span>.</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Cardiac:</p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> (especially <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>), <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> leading to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p></td>
</tr>
<tr>
<td valign="top"><p class="First">G.I.:</p></td>
<td valign="top"><p class="First">Increased salivary, gastric and intestinal secretion, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, increased peristalsis, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>.</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Skeletal Muscle:Â Â Â Â </p></td>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span>.</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Miscellaneous:</p></td>
<td class="Botrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Increased urinary frequency</span> and <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_e77aefb2-ee27-40e6-b619-4b73d7611bf7"></a><a name="section-8"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First">Care should be given when administering this drug to patients with symptoms of myasthenic <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> who are also on anticholinesterase drugs. Since symptoms of anticholinesterase <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (<span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>) may mimic underdosage (myasthenic <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>), their condition may be worsened by the use of this drug. (See <span class="Bold"><a href="#i4i_overdosage_id_9505bfe7-39de-461d-9830-6060667aa82a">OVERDOSAGE</a></span> section for treatment.)</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_9505bfe7-39de-461d-9830-6060667aa82a"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">With drugs of this type, muscarine-like symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, increased bronchial and salivary secretions and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>) often appear with overdosage (<span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>). An important complication that can arise is obstruction of the airway by bronchial secretions. These may be managed with suction (especially if tracheostomy has been performed) and by the use of atropine. Many experts have advocated a wide range of dosages of atropine (for ENLON, see atropine dosage below), but if there are copious secretions, up to 1.2 mg intravenously may be given initially and repeated every 20 minutes until secretions are controlled. Signs of atropine overdosage such as <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, flush and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> should be avoided as tenacious secretions and bronchial plugs may form. A total dose of atropine of 5 to 10 mg or even more may be required. The following steps should be taken in the management of overdosage of ENLON:</p>
<dl>
<dt>1.</dt>
<dd>Adequate respiratory exchange should be maintained by assuring an open airway and the use of assisted respiration augmented by oxygen.</dd>
<dt>2.</dt>
<dd>Cardiac function should be monitored until complete stabilization has been achieved.</dd>
<dt>3.</dt>
<dd>Atropine sulfate in doses of 0.4 to 0.5 mg should be administered intravenously. This may be repeated every 3 to 10 minutes. Because of the short duration of action of ENLON the total dose required will seldom exceed 2 mg.</dd>
<dt>4.</dt>
<dd>If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> occur or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present, appropriate measures should be instituted.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5325ac5b-e9a4-49f8-9ee0-a4cc49945ba9"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">ENLON Test in the Differential Diagnosis of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span><span class="Sup">7-14</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_baca5dcc-d4be-4663-a029-10eab768906c"></a><a name="section-10.1"></a><p></p>
<h2>Intravenous Dosage (Adults)</h2>
<p class="First">A tuberculin syringe containing 1 mL (10 mg) of ENLON is prepared with an intravenous needle, and 0.2 mL (2 mg) is injected intravenously within 15 to 30 seconds. The needle is left in situ. Only if no reaction occurs after 45 seconds is the remaining 0.8 mL (8 mg) injected. If a cholinergic reaction (muscarinic side effects, skeletal <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">muscle fasciculations</span> and increased <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>) occurs after injection of 0.2 mL (2 mg), the test is discontinued and atropine sulfate, 0.4 mg to 0.5 mg, is administered intravenously. After one-half hour the test may be repeated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_709981f0-5346-45f0-85f2-4f7b4b9994c0"></a><a name="section-10.2"></a><p></p>
<h2>Intramuscular Dosage (Adults)</h2>
<p class="First">In adults with inaccessible veins, dosage for intramuscular injection is 1 mL (10 mg) of ENLON. Subjects who demonstrate hyperreactivity to this injection (cholinergic reaction), should be retested after one-half hour with 0.2 mL (2 mg) of ENLON intramuscularly to rule out false-negative reactions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3fe604b-ecf6-4d61-b1e8-091d4c1bafec"></a><a name="section-10.2.1"></a><p></p>
<h3>Dosage in Pediatric Patients</h3>
<p class="First">The intravenous testing dose of ENLON in pediatric patients weighing up to 75 lbs is 0.1 mL (1 mg); above this weight, the dose is 0.2 mL (2 mg). If there is no response after 45 seconds, it may be titrated up to 0.5 mL (5 mg) in pediatric patients under 75 lbs, given in increments of 0.1 mL (1 mg) every 30 to 45 seconds and up to 1 mL (10 mg) in heavier patients. In infants, the recommended dose is 0.05 mL (0.5 mg). Because of technical difficulty with intravenous injection in pediatric patients, the intramuscular route may be used. In pediatric patients weighing up to 75 lbs, 0.2 mL (2 mg) is injected intramuscularly. In pediatric patients weighing more than 75 lbs, 0.5 mL (5 mg) is injected intramuscularly. All signs which would appear with the intravenous test appear with the intramuscular test except that there is a delay of 2 to 10 minutes before a reaction is noted.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad4077a7-db2a-4dea-9a60-15492bc371ef"></a><a name="section-10.3"></a><p></p>
<h2>ENLON Test for Evaluation of Treatment Requirements in <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></h2>
<p class="First">The recommended dose is 0.1 mL to 0.2 mL (1 mg to 2 mg) of ENLON, administered intravenously 1 hour after oral intake of the drug being used in treatment.<span class="Sup">7-11</span> Response will be myasthenic in the undertreated patient, adequate in the controlled patient, and cholinergic in the overtreated patient. Responses to ENLON in myasthenic and nonmyasthenic individuals are summarized in the following chart.<span class="Sup">8</span></p>
<table>
<col width="56%">
<col width="14%">
<col width="15%">
<col width="16%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>
<span class="Bold">Myasthenic Response </span>- occurs in untreated myasthenics and may serve to establish diagnosis; in patients under treatment, indicates that therapy is inadequate.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>
<span class="Bold">Adequate Response </span>- observed in treated patients when therapy is stabilized: a typical response in normal individuals. In addition to this response in non-myasthenics, the phenomenon of forced lid closure is often observed in psychoneurotics.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>
<span class="Bold">Cholinergic Response </span>- seen in myasthenics who have been overtreated with anticholinesterase drugs.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"></td>
<td class="Toprule" valign="top"><p class="First">Myasthenic<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Toprule" valign="top"><p class="First">Adequate<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p></td>
<td class="Toprule" valign="top"><p class="First">Cholinergic<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a></p></td>
</tr>
<tr>
<td valign="top"><p class="First">Muscle Strength (<span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, respiration, limb strength)</p></td>
<td valign="top"><p class="First">Increased</p></td>
<td valign="top"><p class="First">No change</p></td>
<td valign="top"><p class="First">Decreased</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">Fasciculations</span> (orbicularis oculi, facial muscles, limb muscles)</p></td>
<td valign="top"><p class="First">Absent</p></td>
<td valign="top"><p class="First">Present or absent</p></td>
<td valign="top"><p class="First">Present or absent</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Side reactions (<span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>)</p></td>
<td class="Botrule" valign="top"><p class="First">Absent</p></td>
<td class="Botrule" valign="top"><p class="First">Minimal</p></td>
<td class="Botrule" valign="top"><p class="First">Severe</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a2c551d-6f15-4b3a-9059-ee374f79cf1e"></a><a name="section-10.4"></a><p></p>
<h2>ENLON Test in Crisis</h2>
<p class="First">The term <span class="Italics">crisis </span>is applied to the myasthenic whenever severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> with objective ventilatory inadequacy occurs and the response to medication is not predictable. This state may be secondary to a sudden increase in severity of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (myasthenic crisis), or to overtreatment with anticholinesterase drugs (<span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>). </p>
<p>When a patient is apneic, controlled ventilation must be secured immediately in order to avoid <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and irreversible central nervous system damage. No attempt is made to test with ENLON until respiratory exchange is adequate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a1b677d1-c1d0-4faa-9a43-04229b86f4d2"></a><a name="section-10.5"></a><p></p>
<h2>Dosage used at this time is most important</h2>
<p class="First">If the patient is cholinergic, ENLON will cause increased oropharyngeal secretions and further <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the muscles of respiration. If the crisis is myasthenic, the test clearly improves respiration and the patient can be treated with longer-acting intravenous anticholinesterase medication. When the test is performed, there should not be more than 0.2 mL (2 mg) ENLON in the syringe. An intravenous dose of 0.1 mL (1 mg) is given initially. The patientâ€™s heart action is carefully observed. If, after an interval of 1 minute, this dose does not further impair the patient, the remaining 0.1 mL (1 mg) can be injected. If no clear improvement of respiration occurs after 0.2 mL (2 mg) dose, it is usually wisest to discontinue all anticholinesterase drug therapy and secure controlled ventilation by tracheostomy with assisted respiration.<span class="Sup">5</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c7a1b5b-e593-4a18-aafd-e5f108e2a9c4"></a><a name="section-10.6"></a><p></p>
<h2>For Use as a Curare Antagonist</h2>
<p class="First">ENLON should be administered by intravenous injection in 1 mL (10 mg) doses given slowly over a period of 30 to 45 seconds so that the onset of cholinergic reaction can be detected. This dosage may be repeated whenever necessary. The maximal dose for any one patient should be 4 mL (40 mg). Because of its brief effect, ENLON should not be given prior to the administration of curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine: it should be used at the time when its effect is needed. When given to counteract curare overdosage, the effect of each dose on the respiration should be carefully observed before it is repeated, and assisted ventilation should always be employed.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e89647cd-b118-4314-8d0a-8c27fc905176"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ENLON (edrophonium chloride injection, USP):</p>
<p>NDC 67457-190-15 Â Â Â Â Â 15 mL Multiple-Dose Vial</p>
<p>ENLON <span class="Bold">(edrophonium chloride injection, USP) </span><br><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_0f38a890-4805-4808-8f51-c0bf3d895257"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Fisher DM, Cronnelly R, Sharma M, Miller RD. <span class="Italics">Anesthesiology. </span>1984; 428-433.</dd>
<dt>2.</dt>
<dd>Meakin G, Sweet PT, Bevan JC, Bevan DR. Neostigmine and edrophonium as antagonists of pancuronium in infants and children. <span class="Italics">Anesthesiology. </span>1983; 59:316-321.</dd>
<dt>3.</dt>
<dd>Abdulatif M, Al-Ghamdi A, Al-Sanabary M, Abdel-Gaffar ME. <span class="Italics">Br. J. Anesth. </span>1996; 76:239-244.</dd>
<dt>4.</dt>
<dd>Bevan JC, Tousignant C, Stephenson C, et al. Dose responses for neostigmine and edrophonium as antagonists of mivacurium in adults and children. <span class="Italics">Anesthesiology. </span>1996; 84:354-361.</dd>
<dt>5.</dt>
<dd>Kirkegaard-Nielsen H, Meretoja OA, Wirtavuori K. Reversal of atracurium-induced neuromuscular block in paediatric patients. <span class="Italics">Acta Anesthesiol. Scand. </span>1995; 39:906-911.</dd>
<dt>6.</dt>
<dd>Gwinnutt CL, Walker WM, Meakin G. Antagonism of intense atracurium-induced neuromuscular block in children. <span class="Italics">Br. J. Anesth. </span>1991; 67:13-16.</dd>
<dt>7.</dt>
<dd>Osserman KE, Kaplan LI. <span class="Italics">JAMA. </span>1952; 150:265.</dd>
<dt>8.</dt>
<dd>Osserman KE, Kaplan LI, Besson G. <span class="Italics">J Mt Sinai Hosp. </span>1953; 20:165.</dd>
<dt>9.</dt>
<dd>Osserman KE, Kaplan LI. <span class="Italics">Arch Neurol &amp; Psychiat. </span>1953; 70:385.</dd>
<dt>10.</dt>
<dd>Osserman KE, Teng P. <span class="Italics">JAMA. </span>1956; 160:153.</dd>
<dt>11.</dt>
<dd>Osserman KE, Genkins G. <span class="Italics">Ann NY Acad Sci. </span>1966; 135:312.</dd>
<dt>12.</dt>
<dd>Tether JE. Second International Symposium Proceedings, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span>. 1961:444.</dd>
<dt>13.</dt>
<dd>Tether JE. In: HF Conn. <span class="Italics">Current Therapy. </span>Philadelphia: WB Saunders Company; 1960:551.</dd>
<dt>14.</dt>
<dd>Tether JE. In: HF Conn. <span class="Italics">Current Therapy. </span>Philadelphia: WB Saunders Company; 1965:556.</dd>
</dl>
<p class="First">Enlon is a registered trademark of Mylan Teoranta.</p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Akorn, Inc.</span><br>Lake Forest, IL 60045 U.S.A.</p>
<p>BED00N Â Â Â Â Â Rev. 01/13</p>
<p>REVISED JANUARY 2013<br>MI:ENLOIJ:R2</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_774928f2-6721-40ef-ba80-5f5525632760"></a><a name="section-13"></a><p></p>
<h1>Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 150 mg/15 mL</span></p>
<p><span class="Bold">NDC 67457-190-15Â Â Â Â Â 15 mL</span></p>
<p><span class="Bold">Enlon<span class="Sup">Â®</span></span><br><span class="Bold">(edrophonium</span><br><span class="Bold">chloride</span><br><span class="Bold">injection, USP)</span></p>
<p><span class="Bold">150 mg/15 mL</span><br><span class="Bold">(10 mg/mL)</span></p>
<p><span class="Bold">For Intravenous or<br>Intramuscular Use</span></p>
<p><span class="Bold">Rx onlyÂ Â Â Â Â Multiple-Dose Vial</span></p>
<p><span class="Bold">Usual Dosage:</span><br>See accompanying<br>prescribing<br>information.</p>
<p><span class="Bold">Store at 20Â° to</span><br><span class="Bold">25Â°C (68Â° to</span><br><span class="Bold">77Â°F). [See USP</span><br><span class="Bold">Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Made in U.S.A.</p>
<p>MI:190:1C:R2<br>BEDABC Rev. 01/13</p>
<p>Mylan.com</p>
<p><span class="Bold">Each mL contains:</span><br>edrophonium chloride<br>10 mg; 0.45% phenol<br>as a preservative;<br>0.2% sodium sulfite<br>as an antioxidant;<br>buffered with sodium<br>citrate and citric acid.<br>Its pH is adjusted to<br>approximately 5.4.</p>
<p>Enlon is a registered<br>trademark of Mylan Teoranta</p>
<div class="Figure">
<a name="id597"></a><img alt="Enlon (edrophonium chloride injection, USP) 150 mg/ 15 mL Carton Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=98a5a2f6-3194-4202-963f-0fcd28ecadbc&amp;name=91687c49-8f28-499e-9999-9b51154ad379-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ENLONÂ 		
					</strong><br><span class="contentTableReg">edrophonium chloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-190</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>EDROPHONIUM CHLORIDE</strong> (EDROPHONIUM) </td>
<td class="formItem">EDROPHONIUM CHLORIDE</td>
<td class="formItem">10Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">4.5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM SULFATE</strong></td>
<td class="formItem">2Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-190-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088873</td>
<td class="formItem">04/22/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>91687c49-8f28-499e-9999-9b51154ad379</div>
<div>Set id: 98a5a2f6-3194-4202-963f-0fcd28ecadbc</div>
<div>Version: 7</div>
<div>Effective Time: 20130131</div>
</div>
</div>Â <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
